ArticleTrials2025
Remote ischemic conditioning for the prevention of stroke-associated pneumonia (RICA-2): protocol for a multicenter, prospective, randomized, double-blind, sham-controlled phase III trial.
Article in Trials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05982015 (Multicenter, Randomized, Double-blind, Pseudo Treatment-controlled Clinical Study on the Efficacy and Safety of Remote Ischemic Conditioning in Preventing Stroke-associated Pneumonia), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Multicenter, Randomized, Double-blind, Pseudo Treatment-controlled Clinical Study on the Efficacy and Safety of Remote Ischemic Conditioning in Preventing Stroke-associated Pneumonia
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
backgroundStroke-associated pneumonia (SAP) is one of the most common complications in acute ischemic stroke (AIS) patients, affecting 8.5% to nearly 30% of cases and significantly impacting both mortality and long-term survival. As it is closely related to worse outcome, exploring effective preventive strategies, such as remote ischemic conditioning (RIC), is essential for reducing SAP incidence and improving patient outcomes. This study aims to compare the efficacy and safety of RIC for preventing SAP in patients with ischemic stroke within 24 h of symptom onset. METHODS AND
designRICA-2 is a multicenter, randomized, double-blind, parallel-controlled, phase III clinical trial in China. This study will enroll an estimated 1650 patients aged ≥ 18 years within 24 h after AIS symptom onset, with National Institutes of Health Stroke Scale ⩾ 4. The patients will be randomly assigned to RIC or Sham-RIC (1:1) and will be treated with cuff inflation at 200 mmHg or 60 mmHg, respectively. This procedure will be administered twice daily for seven consecutive days. The primary efficacy endpoint is SAP incidence rate. Safety incidence will be recorded and reported. DISCUSSION: RIC has broad clinical application prospects and may play a preventive role in stroke-related pneumonia. RICA-2 is designed to verify whether RIC treatment can serve as an adjuvant therapy for preventing stroke-associated pneumonia and to identify safety concerns.
trial registrationClinicalTrials.gov NCT05982015. Registered on January 22, 2024.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.